About OmicEra Diagnostics
OmicEra Diagnostics is a company based in Munchen (Germany) founded in 2019 was acquired by Exact Sciences in May 2022. The company has 9 employees as of December 31, 2021. OmicEra Diagnostics operates in a competitive market with competitors including Cyrus Biotechnology, Vividion Therapeutics, Seer, Biognosys and ProteinSimple, among others.
- Headquarter Munchen, Germany
- Employees 9 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Omicera Diagnostics Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
9
as on Dec 31, 2021
-
Acquired by
Exact Sciences
(May 10, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of OmicEra Diagnostics
Detailed funding history for OmicEra Diagnostics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in OmicEra Diagnostics
OmicEra Diagnostics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Exact Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Non-invasive molecular diagnostic tests for cancer detection are provided.
|
Locked | Locked | Locked |
Investor details for OmicEra Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OmicEra Diagnostics
Investment portfolio details for OmicEra Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OmicEra Diagnostics
Detailed financials for OmicEra Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Omicera Diagnostics Comparisons
Peer comparison for OmicEra Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OmicEra Diagnostics
OmicEra Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cyrus Biotechnology, Vividion Therapeutics, Seer, Biognosys and ProteinSimple, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cloud-based protein-modeling software is developed for drug discovery.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| Locked | Locked | Locked |
Proteomics services are delivered via discovery and targeted platforms.
|
|
| Locked | Locked | Locked |
Provider tools to help researchers with protein analysis
|
|
| Locked | Locked | Locked |
Small molecule oncology therapeutics are developed for cancer treatment.
|
Detailed competitors of OmicEra Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Omicera Diagnostics
Complete news archive for OmicEra Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OmicEra Diagnostics
OmicEra Diagnostics was founded in 2019.
OmicEra Diagnostics is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
As of Dec 31, 2021, the latest employee count at OmicEra Diagnostics is 9.
OmicEra Diagnostics was established in 2019 in Munich, Germany. Focus is placed on the biotechnology sector, specifically diagnostics through proteomic tools. Software and platforms for analyzing protein data are developed and offered to support research and clinical applications. Operations center on enabling efficient data processing in life sciences. The company addresses needs in omics-based workflows across European markets.
OmicEra Diagnostics's top competitors include Vividion Therapeutics, Cyrus Biotechnology and Biognosys.
OmicEra Diagnostics has 1 investor. Key investors include Exact Sciences.